Warning didn't change for-profit dialysis drug use | Reuters

Blogger's Note: as it applies specifically to ovarian cancer or other cancers there exists many related research/articles - published on this blog and elsewhere

Reuters

"The researchers looked at epoetin alfa, which is marketed as Epogen by Amgen, and darbepoetin alfa, which is marketed as Aranesp also by Amgen. In 2007, the U.S. Food and Drug Administration (FDA) issued a black box warning - the strongest kind - to use as little of the ESAs as possible. Research showed higher doses were associated with an increased risk of death, strokes and heart disease......"